Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2806)	5/6/2010 10:57:09 AM
From: Jibacoa	Respond to of 3722

PBTH is holding on its uptrend in spite of the general market. <g> It is up 2.22%.Volume remains low around 30Ks about 0.35 its ADV bigcharts.marketwatch.com Its CTP, which is a 28 aminoacid C-Terminal peptide, is a small peptide naturally found in the body as a portion of the hormone hCG, and it was found to be related to hCG longer halflife.When it is attached to other proteins it also significantly increases their hallife.<g> PBTH most advanced product is its long acting FSH product, which on Jan28 received marketing approval from the EPA. It has been market by MRK under the name of ELONVA and has a possible market range of $1B Its 2nd product in development is a human growth hormone, with a $3B market potential. It is entering a PII. The drug could potentially be injected 2x/month instead of daily. PBTH had reportedly enough cash on hand to last through the 1st half of 2011 and to be able to complete the PII of RGH and start its PII Its Interferon beta has a $4.8B market potential, and could be used for treatment of MS with much lower side effects. PBTH has other products in its pipeline including EPO; FVIIa; OBES; GL P1 which are on preclinical testing in primates. MRK and PBTH have the exclusive license from Washington University to utilize the CTP technology. The CTP-enhanced therapeutic proteins pipeline has the potential to dominate a $25B market. <g> As mentioned,PBTH received on April 14 a $1.6M grant from the Israel Government for its hGH-CTP. The ACTAY is $7.50. I am long on some shrs of PBTH and plan to continue picking up a few more shrs.<g> bigcharts.marketwatch.com Bernard